Overview
The goal of this clinical trial is to compare the effectiveness of adjunctive low-level light therapy (LLLT) to intense pulsed light (IPL) versus intense pulsed light (IPL) alone for the treatment of meibomian gland dysfunction (MGD).
The main question it aims to answer is does the adjunctive of low-level light therapy (LLLT) to intense pulsed light (IPL) provide more beneficial treatment effects than intense pulsed light (IPL) alone in treating meibomian gland dysfunction (MGD) patients?
Participants will be randomized into 2 groups: adjunctive low-level light therapy (LLLT) to intense pulsed light (IPL) group (ALLLT +IPL) and IPL alone group.
Description
In both the IPL group and the ALLLT+IPL group, the doctor will administer IPL therapy to each participant and apply the Light Modulation® special facial mask to their faces. The assistant nurse will activate the light power, ensuring that the doctor remains blind to treatment allocation. Participants in both groups will receive a conventional treatment for MGD including warm compression and lid hygiene. Moreover, all participants will be advised to use preservative-free artificial tears 4 times daily throughout the study.
Eligibility
Inclusion criteria:
- MGD severity level 2 and above according to the international workshop on MGD
- Fitzpatrick skin type of 1-4 according to sun sensitivity characteristics and appearance of the skin color
Exclusion Criteria:
- History of previous ocular trauma or surgery within the past six months
- Contact lens-wearing patients
- Patients with skin-pigmented lesions in the treatment area
- Pregnancy or breastfeeding patients
- Patients with any uncontrolled ocular or systemic diseases